This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Heavy chain disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Heavy chain disease refers to a group of rare monoclonal gammopathies characterised by elevated levels in the serum and urine of a specific heavy chain.

Three variants are recognised:

  • alpha chain disease - the most common HCD, seen especially in the Mediterranean. Associated with massive infiltration of the lamina propria of the intestine and abdominal lymph nodes by lymphocytes, plasma cell and histiocytes causing villous atrophy and malabsorption. There is an increased risk of gastrointestinal lymphoma.

  • gamma chain disease - seen most frequently in the elderly. The clinical presentation resembles a malignant lymphoma more than a multiple myeloma. Principle features are lymphadenopathy, anaemia, and fever; often, splenomegaly or hepatomegaly

  • mu chain disease - the least common HCD, seen usually in chronic lymphocytic leukaemia. Splenomegaly and hepatomegaly are common; lymphadenopathy is rare.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.